Journal
PHARMACOGENOMICS
Volume 22, Issue 14, Pages 927-937Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/pgs-2021-0044
Keywords
opioids; pain; pain management; pharmacogenetics; pharmacogenomics
Categories
Ask authors/readers for more resources
The implementation of pharmacogenomics in opioid management faces a series of barriers, including the need for clinical and economic research, education and training, policy and public health considerations, as well as legal and ethical issues.
Opioid misuse and mismanagement has been a public health crisis for several years. Pharmacogenomics (PGx) has been proposed as another tool to enhance opioid selection and optimization, with recent studies demonstrating successful implementation and outcomes. However, broad engagement with PGx for opioid management is presently limited. The purpose of this Perspective is to highlight a series of barriers to PGx implementation within the specific context of opioid management. Areas of advancement needed for more robust pharmacogenomic engagement with opioids will be discussed, including clinical and economic research needs, education and training needs, policy and public health considerations, as well as legal and ethical issues. Continuing efforts to address these issues may help to further operationalize PGx toward improving opioid use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available